You are an Investor…

If you are an Angel in the LifeScience Sector or Pre-Seed/Seed VC

Leveraging QUASY for De-risking Investments and Boosting Enterprise Value

De-risking investments in the life sciences sector, especially for startups, is a crucial concept that involves reducing the uncertainty and potential risks associated with these investments. This is particularly important in the life sciences due to the high costs, extensive regulatory requirements, and long development timelines typical in this field. Here’s a breakdown of the concept:

Understanding the Risks in Life Sciences

1. Scientific and Technological Risk: This involves the uncertainty about whether a proposed technology or scientific concept will work as expected. For life sciences startups, this often means proving that a drug or medical device is effective and safe.

2. Regulatory Risk: Startups in this sector must navigate complex regulatory landscapes. Approval from bodies like the FDA or EMA is essential but not guaranteed.

3. Market Risk: Even if a product is scientifically sound and approved by regulatory authorities, there’s no guarantee it will be commercially successful.

4. Financial Risk: Life sciences ventures often require substantial capital investment with long periods before seeing any return on investment.

5. Startup Risks: The team falls apart or loses the aim.
   
   

Strategies for De-risking

1. Robust Due Diligence: Investors conduct thorough due diligence, scrutinizing the startup’s technology, business plan, market potential, and regulatory strategy.

2. Milestone-Based Funding: Investments are often structured around achieving specific milestones, such as clinical trial phases or regulatory approvals, to manage financial exposure.

3. Leveraging Partnerships and Alliances: Startups can form strategic alliances with established companies, benefiting from their experience, resources, and credibility.

4. Regulatory Expertise: Employing or consulting with regulatory experts can help navigate complex approval processes more efficiently.

5. Market Analysis and Validation: Conducting thorough market research and validation studies to ensure there is a demand for the product and a viable business model.

6. Quality Management Systems (QMS) like QUASY: Implementing robust QMS tools can ensure compliance, improve operational efficiency, and reduce the risk of costly errors or regulatory setbacks.
   
   

Impact of De-risking

• Attracts More Investment: De-risked ventures are more attractive to investors and business partners as they present a more balanced risk-reward profile.

• Increases Chances of Success: By systematically addressing and mitigating risks, startups can increase their chances of achieving commercial and scientific success.

• Builds Credibility: A well-devised de-risking strategy can enhance the credibility of a startup in the eyes of partners, investors, and regulatory bodies.

De-risking is not about eliminating all risks, as that is impossible in the inherently uncertain field of life sciences. Instead, it’s about understanding, managing, and mitigating risks to make more informed decisions and improve the likelihood of successful outcomes.

Benefits of QUASY for Investors:

• Risk Mitigation: As outlined in the different risks above there are plenty of issues arising when starting in LifeSciences. By implementing QUASY right from the get go you:

  • Reduce regulatory issues by working compliant from the start, reducing legal and financial risks.

  • Reduce issues with personnel rotation due to standardized processes.

  • Allow for partnerships with industry partners

  • Allow for proven data integrity

  • Increase the Enterprise Value, by improving trust and compliance.

• Operational Efficiency: Running an QMS/eQMS allow to increase opeartional efficiency. Running QUASY in one of our trusted environments will ensure you reach this goal.

Getting Started with QUASY:

• We can hedge your risk by implementing a QMS within days or weeks (instead of months) by providing our solution, right when you decide to get serious. With barely any interruption in the Startups business continuity, the companies can focus on developing the product, but in a robust way.

• We may partner up with you providing discounted pricing.

• Contact sales@austrianpharmaservices.com
  
  
  

If you are a traditional financial investor feel free to reach out to discuss options.